{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:23:19Z","timestamp":1794961399303,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7756","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2019,5,16]]},"DOI":"10.1038\/s41586-019-1162-y","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T14:03:44Z","timestamp":1556719424000},"page":"428-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":453,"title":["Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy"],"prefix":"10.1038","volume":"569","author":[{"given":"Elisabeth","family":"Perez-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Minute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itziar","family":"Otano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maite","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmen","family":"Ochoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Belsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"de Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Esperanza","family":"Rodriguez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Perez-Gracia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Marquez-Rodas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casilda","family":"Llacer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"de Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Teijeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Berraondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,1]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok, J. D., Rollin, L. & Larkin, J. Nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 2503\u20132504 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR2","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277\u20131290 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N. Engl. J. Med. 378, 2093\u20132104 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","volume":"369","author":"JD Wolchok","year":"2013","unstructured":"Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122\u2013133 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR5","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275\u20134280 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1162_CR6","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 73, 3591\u20133603 (2013).","journal-title":"Cancer Res."},{"key":"1162_CR7","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","volume":"20","author":"DA Wainwright","year":"2014","unstructured":"Wainwright, D. A. et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 20, 5290\u20135301 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1162_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2051-1426-2-3","volume":"2","author":"S Spranger","year":"2014","unstructured":"Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3 (2014).","journal-title":"J. Immunother. Cancer"},{"key":"1162_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S1470-2045(17)30231-0","volume":"18","author":"PA Ascierto","year":"2017","unstructured":"Ascierto, P. A. et al. Ipilimumab 10 mg\/kg versus ipilimumab 3 mg\/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 18, 611\u2013622 (2017).","journal-title":"Lancet Oncol."},{"key":"1162_CR11","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A. & Hellmann, M. D. Adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 1163\u20131165 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1162_CR12","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1073\/pnas.94.4.1441","volume":"94","author":"Y Yamada","year":"1997","unstructured":"Yamada, Y., Kirillova, I., Peschon, J. J. & Fausto, N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl Acad. Sci. USA 94, 1441\u20131446 (1997).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1162_CR13","first-page":"238","volume":"69","author":"HS Cooper","year":"1993","unstructured":"Cooper, H. S., Murthy, S. N., Shah, R. S. & Sedergran, D. J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69, 238\u2013249 (1993).","journal-title":"Lab. Invest."},{"key":"1162_CR14","doi-asserted-by":"publisher","first-page":"6016","DOI":"10.3748\/wjg.v23.i33.6016","volume":"23","author":"DD Eichele","year":"2017","unstructured":"Eichele, D. D. & Kharbanda, K. K. Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol. 23, 6016\u20136029 (2017).","journal-title":"World J. Gastroenterol."},{"key":"1162_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/MOG.0000000000000031","volume":"30","author":"W Blonski","year":"2014","unstructured":"Blonski, W., Buchner, A. M. & Lichtenstein, G. R. Treatment of ulcerative colitis. Curr. Opin. Gastroenterol. 30, 84\u201396 (2014).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"1162_CR16","first-page":"560","volume":"118","author":"BK Popivanova","year":"2008","unstructured":"Popivanova, B. K. et al. Blocking TNF-\u03b1 in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest. 118, 560\u2013570 (2008).","journal-title":"J. Clin. Invest."},{"key":"1162_CR17","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1158\/1078-0432.CCR-11-0945","volume":"17","author":"J Coward","year":"2011","unstructured":"Coward, J. et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17, 6083\u20136096 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1162_CR18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","volume":"67","author":"TA Mace","year":"2018","unstructured":"Mace, T. A. et al. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer. Gut 67, 320\u2013332 (2018).","journal-title":"Gut"},{"key":"1162_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02358-7","volume":"8","author":"F Bertrand","year":"2017","unstructured":"Bertrand, F. et al. TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat. Commun. 8, 2256 (2017).","journal-title":"Nat. Commun."},{"key":"1162_CR20","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.7150\/thno.15253","volume":"6","author":"M Hettich","year":"2016","unstructured":"Hettich, M., Braun, F., Bartholom\u00e4, M. D., Schirmbeck, R. & Niedermann, G. High-resolution PET Imaging with therapeutic antibody-based PD-1\/PD-L1 checkpoint tracers. Theranostics 6, 1629\u20131640 (2016).","journal-title":"Theranostics"},{"key":"1162_CR21","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","volume":"50","author":"S Kurtulus","year":"2019","unstructured":"Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1\u2212CD8+ tumor-infiltrating T cells. Immunity 50, 181\u2013194.e6 (2019).","journal-title":"Immunity"},{"key":"1162_CR22","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195\u2013211.e10 (2019).","journal-title":"Immunity"},{"key":"1162_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1615\/CritRevImmunol.2014009988","volume":"34","author":"R Arakaki","year":"2014","unstructured":"Arakaki, R., Yamada, A., Kudo, Y., Hayashi, Y. & Ishimaru, N. Mechanism of activation-induced cell death of T cells and regulation of FasL expression. Crit. Rev. Immunol. 34, 301\u2013314 (2014).","journal-title":"Crit. Rev. Immunol."},{"key":"1162_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/377348a0","volume":"377","author":"L Zheng","year":"1995","unstructured":"Zheng, L. et al. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377, 348\u2013351 (1995).","journal-title":"Nature"},{"key":"1162_CR25","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1158\/0008-5472.CAN-14-3510","volume":"75","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed, M. F. et al. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2\u2212\/\u2212IL2R\u03b3null immunodeficient mice. Cancer Res. 75, 3466\u20133478 (2015).","journal-title":"Cancer Res."},{"key":"1162_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361\u2013371 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"1162_CR27","doi-asserted-by":"publisher","first-page":"5950","DOI":"10.1200\/JCO.2005.04.127","volume":"23","author":"S Madhusudan","year":"2005","unstructured":"Madhusudan, S. et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J. Clin. Oncol. 23, 5950\u20135959 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1162_CR28","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1200\/JCO.2007.11.2136","volume":"25","author":"ML Harrison","year":"2007","unstructured":"Harrison, M. L. et al. Tumor necrosis factor \u03b1 as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J. Clin. Oncol. 25, 4542\u20134549 (2007).","journal-title":"J. Clin. Oncol."},{"key":"1162_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cyto.2016.04.012","volume":"83","author":"YT Xiao","year":"2016","unstructured":"Xiao, Y. T., Yan, W. H., Cao, Y., Yan, J. K. & Cai, W. Neutralization of IL-6 and TNF-\u03b1 ameliorates intestinal permeability in DSS-induced colitis. Cytokine 83, 189\u2013192 (2016).","journal-title":"Cytokine"},{"key":"1162_CR30","first-page":"G544","volume":"274","author":"M M\u00e4hler","year":"1998","unstructured":"M\u00e4hler, M. et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am. J. Physiol. 274, G544\u2013G551 (1998).","journal-title":"Am. J. Physiol."},{"key":"1162_CR31","first-page":"2019","volume":"7","author":"Q Tang","year":"2014","unstructured":"Tang, Q. et al. Role of far upstream element binding protein 1 in colonic epithelial disruption during dextran sulphate sodium-induced murine colitis. Int. J. Clin. Exp. Pathol. 7, 2019\u20132031 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."}],"updated-by":[{"DOI":"10.1038\/s41586-025-09672-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1162-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1162-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1162-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:03:50Z","timestamp":1759881830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-019-1162-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,1]]},"references-count":31,"journal-issue":{"issue":"7756","published-print":{"date-parts":[[2019,5,16]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1038\/s41586-019-1162-y","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735650776.793561990","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.735650776.793563225","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,1]]},"assertion":[{"value":"14 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-025-09672-x","URL":"https:\/\/doi.org\/10.1038\/s41586-025-09672-x","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.M. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, CYTOMX, Incyte, MedImmune, Tusk, F-Star, Genmab, Molecular Partners, Alligator, Bioncotech, MSD, Merck-Serono and Bayer, and research funding from Roche, BMS, Alligator and Bioncotech. P.B. reports advisory roles with Tusk and Moderna, research funding from Sanofi, Moderna and Bavarian Nordic and speaker honoraria from BMS, MSD, Novartis and AstraZeneca. I.M.-R. reports advisory roles with Roche-Genentech, Bristol-Myers Squibb, Incyte, Merck, Amgen, Pierre Fabre, Novartis, and Bioncotech. J.L.P.-G. reports advisory roles with Roche, MSD and BMS, travel support from Roche, BMS and MSD and research funding from Roche, BMS, MSD, Ipsen, Eisai, Incyte and Janssen. E.P.-R. reports speaker honoraria and travel support from BMS, MSD and Novartis. The rest of the authors have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}